Drug intelligence / Profile preview

3E8

Development stage: Unknown
Lead developer: ViroMed
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

3E8 is a humanized monoclonal antibody developed by ViroMed, with exclusive worldwide development and commercialization rights granted to Enlyten Medical Technologies. It targets the tumor-associated glycoprotein TAG-72 and is being developed for use in cancer detection and targeted drug delivery. Enlyten Medical Technologies intends to advance 3E8 into a Phase 1 imaging trial.

Targets

TAG-72

Beyond the preview

Go deeper on 3E8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3E8.

Explore the full profile